What Is FST344 Same as Follistatin-344? (Structure

What Is FST344 Same as Follistatin-344? (Structure Explained)

Research databases list both 'FST344' and 'Follistatin-344' in published trials on myostatin inhibition and muscle growth. And if you're navigating peptide literature for the first time, the dual naming creates unnecessary confusion. Here's what matters: FST344 and Follistatin-344 refer to the exact same peptide sequence. The nomenclature difference exists because molecular biology naming conventions abbreviate the protein name (Follistatin → FST) and append the amino acid count (344). The longer form appears in clinical publications; the shorthand version dominates laboratory protocols and supplier catalogs.

Our team works with research institutions sourcing peptides for muscle physiology studies, and we've seen this naming pattern cause procurement delays when researchers don't realise they're ordering the same compound under two different catalog labels. The distinction that actually matters isn't FST344 vs Follistatin-344. It's understanding which Follistatin isoform you're working with and why the 344-residue variant behaves differently from the 315-residue form.

Is FST344 the same compound as Follistatin-344?

Yes. FST344 is simply the abbreviated nomenclature for Follistatin-344, the 344-amino acid isoform of the myostatin-binding protein Follistatin. Both terms describe the identical molecular structure: a glycoprotein that binds and neutralises myostatin (GDF-8), the negative regulator of muscle growth. The number 344 refers to the total amino acid residue count in this specific splice variant. In research contexts, FST344 serves as catalog shorthand while Follistatin-344 appears in peer-reviewed publications. But the peptide sequence, mechanism, and biological activity remain unchanged regardless of which label you encounter.

The confusion stems from peptide suppliers listing the same product under both names without clarifying they're equivalent. What genuinely differs are the isoforms. Follistatin exists as FST288, FST303, FST315, and FST344, each with distinct pharmacokinetic profiles and tissue affinities. FST344, the focus here, circulates longer in plasma due to its lack of a heparin-binding domain, making it more suitable for systemic myostatin inhibition research compared to the shorter, tissue-bound FST315 variant. This article covers the structural basis for the FST344 nomenclature, the functional differences between Follistatin isoforms, and what researchers should verify when sourcing this peptide for laboratory work.

The Molecular Structure Behind the FST344 Designation

Follistatin's naming convention follows standard protein nomenclature: the gene abbreviation (FST) followed by the amino acid chain length. The human Follistatin gene undergoes alternative splicing to produce multiple isoforms. FST344 results from the inclusion of exon 6, which adds a 27-amino acid C-terminal extension absent in the shorter FST315 variant. This extension critically alters the protein's pharmacokinetics: FST315 contains a heparin-binding domain that tethers it to cell surfaces and extracellular matrix components, confining its activity to local tissues. FST344 lacks this domain, allowing it to circulate freely in plasma with a half-life extending beyond 3 hours in murine models. Substantially longer than FST315's rapid tissue sequestration.

The 344-residue structure consists of an N-terminal domain followed by three Follistatin domains (FSD1, FSD2, FSD3), each containing approximately 73–77 amino acids with conserved cysteine residues forming disulfide bonds that stabilise the protein's tertiary structure. These domains collectively create the binding interface for myostatin and other TGF-β superfamily members. The absence of the heparin-binding motif in FST344 means it binds myostatin in circulation rather than at the muscle fibre surface. A distinction that influences experimental design in muscle hypertrophy studies. Research published in the Journal of Biological Chemistry demonstrated that systemic administration of FST344 produces whole-body myostatin inhibition, whereas FST315 requires local injection to achieve measurable effects in target muscle groups.

When sourcing FST344 for research, purity verification should include mass spectrometry confirming the 37.8 kDa molecular weight (accounting for glycosylation) and sequencing to verify the presence of the exon 6-encoded C-terminal extension. We've guided research teams through high-purity peptide sourcing where catalog listings use interchangeable nomenclature. The critical specification isn't whether the label reads 'FST344' or 'Follistatin-344,' but whether the supplier can provide HPLC chromatograms and sequencing data confirming the 344-residue isoform rather than the shorter FST315 variant.

FST344 vs FST315: Why the Isoform Distinction Matters

The functional difference between FST344 and FST315 extends beyond molecular weight. It fundamentally changes how the protein distributes in vivo and where it exerts myostatin inhibition. FST315 binds to heparan sulfate proteoglycans on cell surfaces, localising its activity to tissue microenvironments. This makes it effective for localised applications. Intramuscular injection studies targeting specific muscle groups. But unsuitable for systemic myostatin suppression. FST344's lack of the heparin-binding domain allows it to remain in circulation, binding myostatin in plasma before it reaches muscle tissue receptors. A 2009 study in Molecular Endocrinology quantified this: intravenous FST344 produced measurable increases in muscle mass across multiple muscle groups, while equivalent doses of FST315 showed no systemic effect unless injected directly into target muscles.

The half-life difference compounds over repeated dosing schedules. FST344's extended plasma residence time (3+ hours in rodent models, longer in larger species based on allometric scaling) means less frequent administration achieves sustained myostatin inhibition. FST315 clears from circulation within 30–60 minutes as it binds to tissue-resident proteoglycans, requiring either continuous infusion or multiple daily injections to maintain therapeutic levels. For research protocols examining chronic myostatin suppression. Studies running 4–12 weeks. FST344's pharmacokinetics align better with practical dosing schedules.

The glycosylation state also varies between isoforms. Both FST344 and FST315 undergo N-linked glycosylation, but the extent and pattern differ based on the cellular context of post-translational modification. Recombinant FST344 produced in mammalian cell lines (CHO, HEK293) exhibits glycosylation patterns closer to native human Follistatin than bacterial expression systems, which lack glycosylation machinery entirely. This matters because glycosylation affects protein stability and receptor binding affinity. Studies using non-glycosylated FST344 from E. coli expression systems may not replicate results from mammalian-produced variants. When evaluating FST344 sources, verify the expression system used and request glycosylation analysis if the research application demands native-like post-translational modifications.

FST344 Same as Follistatin-344: Comparative Analysis

What If: FST344 Research Scenarios

What If a Supplier Lists Both FST344 and Follistatin-344 as Separate Products?

Request the certificate of analysis (CoA) for both listings and compare the molecular weight, amino acid sequence, and HPLC retention times. If the specifications match identically. Both showing 344 residues and a molecular weight near 37.8 kDa. They're the same product under different catalog names, and you should select based on price and lot purity. If the molecular weights differ, one listing may be incorrectly labeled or may refer to a truncated or modified variant. We've encountered cases where 'FST344' referred to a non-glycosylated bacterial expression product while 'Follistatin-344' designated the glycosylated mammalian-cell product. The sequence was identical, but post-translational modifications differed. Always verify the expression system and request sequencing data before assuming equivalence.

What If I Accidentally Ordered FST315 Instead of FST344 for a Systemic Study?

FST315 won't produce the systemic myostatin inhibition you need. Its heparin-binding domain causes rapid tissue sequestration, confining activity to the injection site. If the study design requires whole-body effects (cachexia models, age-related muscle loss, systemic myostatin suppression), FST315 is functionally unsuitable regardless of dose. You'll need to reorder FST344 and redesign the dosing protocol. If the compound has already shipped, some research teams have salvaged FST315 for preliminary dose-finding work via intramuscular injection in target muscles, treating it as a localised proof-of-concept before transitioning to systemic FST344 administration. The data won't be directly comparable, but it can inform safety and tolerability parameters.

What If the Molecular Weight on the CoA Doesn't Match 37.8 kDa?

Glycosylation extent varies between production batches and expression systems, so some variance is expected. Mammalian-produced FST344 typically ranges from 37–39 kDa depending on the glycosylation pattern. If the molecular weight is significantly lower (32–34 kDa), you may have received non-glycosylated FST344 from a bacterial expression system, which lacks the post-translational modifications present in native Follistatin. This doesn't mean the peptide is inactive, but receptor binding affinity and in vivo stability may differ from published studies using mammalian-expressed variants. If the weight exceeds 40 kDa, request sequencing to confirm you received FST344 and not a fusion protein or pegylated variant. Mass spectrometry should resolve the discrepancy. Any deviation beyond ±2 kDa from the expected range warrants confirmation before proceeding with the research protocol.

The Blunt Truth About FST344 Nomenclature Confusion

Here's the honest answer: the FST344 vs Follistatin-344 confusion is entirely artificial. They're the same peptide. Suppliers use both labels interchangeably because some researchers search by gene abbreviation (FST) and others by full protein name (Follistatin). What creates real procurement errors isn't the naming variation. It's failure to verify the isoform. A catalog listing 'Follistatin' without specifying the residue count could be FST288, FST315, or FST344, and the functional differences are enormous. The 315-residue variant won't work for systemic studies. The 288-residue form binds too tightly to tissue matrices for most myostatin research applications. If your supplier can't immediately confirm which isoform they're selling, find a different supplier. The information in this article is for educational purposes. Peptide sourcing, purity verification, and experimental design decisions should be made in consultation with qualified research personnel familiar with your specific study protocol.

The bigger issue is glycosylation transparency. Many suppliers don't disclose the expression system used to produce recombinant FST344, which directly impacts whether the peptide is glycosylated. Bacterial systems (cheaper, faster production) yield non-glycosylated protein. Mammalian systems (more expensive, slower) produce glycosylated variants that more closely mimic native human Follistatin. If your research application depends on native-like receptor binding. Particularly studies comparing FST344 efficacy to endogenous Follistatin levels. The expression system matters as much as the isoform. A 344-residue sequence produced in E. coli isn't functionally identical to the same sequence produced in CHO cells, even though both are technically 'FST344.' Demand clarity on production methods before committing to a supplier.

Researchers often assume that because fst344 same as follistatin-344 in nomenclature, all products labeled either way will perform identically. That's only true if the isoform, glycosylation state, and purity level match. We've reviewed procurement errors where teams ordered 'Follistatin' assuming it was FST344, received FST315, and didn't discover the error until the study endpoint when systemic effects failed to materialise. Sequence verification isn't optional. It's the minimum due diligence for any peptide-based research protocol. If the CoA doesn't include sequencing data confirming the 344-residue structure and glycosylation analysis for mammalian-produced batches, you're accepting the supplier's labeling on faith. That's not how rigorous research procurement works.

Understanding that fst344 same as follistatin-344 resolves the naming confusion. But it doesn't guarantee you'll receive the correct isoform unless you verify the specifications. The catalog label is less important than the molecular characterisation data. Focus on that, and the nomenclature becomes irrelevant.

If you're sourcing research-grade peptides and need transparent documentation on isoform identity and post-translational modifications, our commitment to precision extends across compounds like Thymalin, Dihexa, and our full peptide collection. Every batch includes HPLC verification and sequence confirmation so you know exactly what's in the vial before it enters your protocol.

The naming overlap between FST344 and Follistatin-344 doesn't create functional ambiguity if you verify the isoform and production method. The peptide works the same regardless of which label appears on the catalog page. What changes outcomes is whether you received the isoform your study design requires and whether the glycosylation state matches the pharmacokinetic assumptions in your protocol. Verify those two factors, and the rest is just paperwork.